Alterations of Gut Microbiota After Biliopancreatic Diversion with Duodenal Switch in Wistar Rats
The biliopancreatic diversion with duodenal switch (BPD/DS) represents the most effective surgical procedure for the treatment of severe obesity and associated type 2 diabetes. The mechanisms whereby BPD/DS exerts its positive metabolic effects have however yet to be fully delineated. The objective of this study was to distinguish the effects of the two components of BPD/DS, namely the sleeve gastrectomy (SG) and the DS derivation, on gut microbiota, and to appraise whether changes in microbial composition are linked with surgery-induced metabolic benefits.
BPD/DS, DS, and SG were performed in Wistar rats fed a standard chow diet. Body weight and energy intake were measured daily during 8 weeks post-surgery, at which time glucagon-like peptide 1 (GLP-1), peptide tyrosine tyrosine (PYY), insulin, and glucose were measured. Fecal samples were collected prior to surgery and at 2 and 8 weeks post-surgery. Intraluminal contents of the alimentary, biliopancreatic, and common limbs (resulting from BPD/DS) were taken from the proximal portion of each limb. Fecal and small intestinal limb samples were analyzed by 16S ribosomal RNA gene sequencing.
BPD/DS and DS led to lower digestible energy intake (P = 0.0007 and P = 0.0002, respectively), reduced weight gain (P < 0.0001) and body fat mass (P < 0.0001), improved glucose metabolism, and increased GLP-1 (P = 0.0437, SHAM versus DS) and PYY levels (P < 0.0001). These effects were associated with major alterations of both the fecal and small intestinal microbiota, as revealed by significant decrease in bacterial richness and diversity at 2 (P < 0.0001, Chao1 index; P < 0.0001, Shannon index) and 8 weeks (P = 0.0159, SHAM versus DS, Chao1 index; P = 0.0219, SHAM versus DS, P = 0.0472, SHAM versus BPD/DS, Shannon index) post-surgery in BPD/DS and DS, and increased proportions of Bifidobacteriales (a 60% increase in both groups) but reduced Clostridiales (a 50% decrease and a 90% decrease respectively), which were mostly accounted at the genus level by higher relative abundance of Bifidobacterium in both the fecal and intestinal limb samples, as well as reduced abundance of Peptostreptococcaceae and Clostridiaceae in the small intestine. Those effects were not seen in SG rats.
The metabolic benefits following BPD/DS are seemingly due to the DS component of the surgery. Furthermore, BPD/DS causes marked alterations in fecal and small intestinal microbiota resulting in reduced bacterial diversity and richness. Our data further suggest that increased abundance of Bifidobacterium and reduced level of two Clostridiales species in the gut microbiota might contribute to the positive metabolic outcomes of BPD/DS.
KeywordsBariatric surgery Body weight Body fat Glucose metabolism Gastrointestinal hormones Glucagon-like peptide 1 (GLP-1) Peptide tyrosine tyrosine (PYY) Bifidobacteriales Clostridiales
Bariatric surgery represents the most effective treatment of severe obesity . Among the procedures currently used, vertical sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), and biliopancreatic diversion with duodenal switch (BPD/DS) have all proved to efficiently reduce excess fat and resolve, to various degrees, obesity-associated co-morbidities such as type 2 diabetes (T2D). RYGB and SG are currently the most performed surgeries . They are preferred over BPD/DS, which has been questionably associated with malnutrition . BPD/DS is however the most efficacious surgery to reduce excess fat loss and to alleviate T2D . It is a two-stage procedure including a SG and a biliopancreatic derivation component (duodenal switch (DS)). DS brings the biliopancreatic secretions to the distal ileum and thereby causes malabsorption. Recent data obtained in laboratory rats have demonstrated that the effects of BPD/DS are largely attributable to the DS or malabsorptive component of the surgery [5, 6].
The beneficial effects of bariatric surgery have been inevitably associated with gut alterations . The surgery increases the secretion of gut hormones GLP-1 and PYY, which are hormones known to reduce food intake and, as for GLP-1, to produce incretin effects [8, 9]. In addition, bariatric surgery also appears to induce favorable changes on the gut microbiota [10, 11, 12]. For instance, RYGB increases the amount of Gammaproteobacteria whereas it decreases that of Clostridia [13, 14] thereby creating a microbiota potentially favoring weight loss and improving metabolic health [14, 15]. Despite recent progress, our current understanding of the impact of bariatric surgery on the gut microbiota is still scarce, especially with regard to certain types of surgery such as BPD/DS. The present study aimed to address the effects of BPD/DS on the gut microbiota and to distinguish the respective effects of the two components of the BPD/DS, namely SG and DS (referring to the derivation per se). We therefore analyzed the gut microbiota in SHAM, SG, DS, and BPD/DS groups of rats. We hypothesized that (i) the gut microbiota changes over time after BPD/DS, (ii) the two components of BPD/DS have different impacts on gut microbiota (as they have different impacts on energy balance), and (iii) there are distinctive changes in the gut microbiota at different levels of the intestine.
Materials and Methods
Male Wistar rats weighting between 415 and 440 g (Charles River Canada St-Constant, QC, Canada) were housed individually in plastic cages and kept on a 12:12 h light-dark cycle (lights turned on at 0700 hours) at an ambient temperature of 23 °C ± 1 °C. The rats had access to a standard chow diet (2018 Teklad Global 18% Protein Rodent Diet, Harlan Laboratories, Montreal, QC, Canada; grams per 100 g: crude protein 18.6, fat 6.2, digestible carbohydrate 44.2, crude fiber 3.5, neutral detergent fiber 14.7, and ash 5.3). The protocol was approved by the Université Laval Animal Care and Use Committee, and animals were cared according to the Canadian Guide for the Care and Use of Laboratory Animals.
Bariatric Surgery Procedures
The rats were divided into BPD/DS, SG, DS, and SHAM groups. BPD/DS was performed as previously described and illustrated [5, 16]. BPD/DS consisted of a vertical SG and a DS. SG consisted of the removal of the two-thirds of the stomach to restrict the amount of food ingested. The DS consisted of a reengineering of the intestine to bring the biliopancreatic secretion at the level of the ileum. The intestine was cut 50 cm above the ileocecal junction, and the proximal part of the intestine was anastomosed at 20 cm from the ileocecal junction to create a common limb. The distal part of the intestine was anastomosed to the duodenum to create the alimentary limb. The total length of the rat intestine is approximately 125 cm. The absolute lengths of the limbs that were created were as follows: alimentary limb = 30 cm, common limb = 20 cm, biliopancreatic limb ~ 75 cm. This anastomosis was performed using an end-to-side technique at about 1.5 cm from the pylorus. The duodenum was ligated with silk between the duodenal anastomosis and the biliopancreatic duct to separate the biliopancreatic limb and ensure the channeling of food only into the alimentary limb. In SG animals, only the gastrectomy was performed and, in DS rats, only the derivation was performed. The SHAM surgery consisted of a midline laparotomy, the handling of intestines and stomach, and the suture of the abdominal wall.
At the time of sacrifice, the duodenal closure was verified in DS and BPD/DS rats and only animals maintaining intact closure (absence of food in the biliopancreatic limb) were included in the statistical analyses. The study began with a total of 29 rats. It ended with 21 rats (success rate of 72%). Two DS rats were sacrificed due to gastroesophageal refluxes, and 4 DS rats died after the surgery. None of the BPD/DS rats died during the protocol but 2 were excluded from the analyses because food was found in the biliopancreatic limb. Twenty-one rats were used for metabolic studies and gut microbiota analysis: DS n = 4, BPD/DS n = 5, SHAM n = 6, SG n = 6.
Weight and Tissue Weight
Rats were weighted daily throughout the study. They were killed at the end of the eighth postoperative week with an intraperitoneal (ip) overdose of ketamine (60 mg/kg) and xylazine (7.5 mg/kg). The liver, spleen, interscapular brown adipose tissue (BAT), and inguinal and retroperitoneal white adipose tissues (iWAT, rpWAT) were then excised and weighted.
Food and Energy Intake
Food intake was measured daily. The gross energy intake (GEI) was determined by multiplying daily food intake in grams by the gross energy density of the diet, which was determined to be 17.3 kJ/g by bomb calorimetry (Parr 6100 calorimeter). During this protocol, we did not collect the feces and therefore did not assess the energy lost in the feces. Thus, the digestible energy intake (DEI), which represents GEI minus the energy loss in the feces, was calculated by multiplying GEI on day 28 by DEI/GEI ratio calculated in a previous study, in which rats were subjected to exactly the same conditions as the rats in the present study and in which fecal energy was determined to directly determine DEI . We used the following ratios: SHAM = 0.84, SG = 0.84, DS = 0.72; BPD/DS = 0.74.
Plasma Glucose and Hormones
After 5 h of fasting, rats were sacrificed and blood was collected by cardiac puncture, using syringes containing ethylenediaminetetraacetic acid (EDTA) 0.5 M. Postprandial levels of the gut hormones and metabolites were measured as described below. In order to inhibit the activity of proteinases, part of the collected blood was mixed with aprotinin (500 U/ml) and a DPP IV inhibitor (10 μl/ml blood) before centrifugation (3500 rpm for 10 min at 4 °C). Supernatants were transferred in separate tubes and stored at − 80 °C. An Elisa kit was used for the measurement of plasma PYY, insulin (Milliplex® MAP kit, Billerica, MA, USA), and GLP-1 7–36 dosage (Alpco), and the Wako Autokit Glucose for the measurement of plasma glucose (Wako Diagnostics, Mountain View, CA, USA).
Gut Microbiota Analyses
Fecal Sampling and DNA Extraction
Fecal samples were collected in a sterile plastic cup, prior to surgery as well as at 2 and 8 weeks after surgery, and stored at − 80 °C pending further processing. Additionally, gut samples were collected at the time of sacrifice. In the BPD/DS- and DS-operated rats, intraluminal content of the alimentary, biliopancreatic, and common limbs were taken from the proximal portion of each limb (the 10 first centimeters of each limb were cut and the luminal content emptied in a sterile cup). In the SHAM- and SG-operated rats, intraluminal contents were obtained from corresponding levels of the small intestine. Then, samples were stored at − 80 °C until DNA extraction. Genomic DNA was extracted using the FastDNA® Spin Kit for Soil (MP Biomedicals, Solon, OH, USA) following the manufacturer’s instruction by using a combination of physical cell-disruption (bead beater) and silica column purification, some modifications were added for better yields. Briefly, approximately 100 mg of feces is manually crushed in sodium phosphate and MT buffers (MP Bio) and mixed with lysing matrix particles. Homogenization is carried out in a MiniBeadBeater (Bertin instruments, Montigny-le-Bretonneux, France) to break bacterial cells. After centrifugation (10 min, 14,000g), supernatant is treated with a protein precipitation solution (MP Bio) in order to remove proteins present in large quantities in feces. Then, a SEWS-M wash solution (MP Bio) is added to remove impurities once DNA is bound to the binding matrix. After two centrifugations (2 min, 14,000g), DNA is eluted with 50 μl DNase-free water. Total extracted DNA is quantified with a BioDrop spectrophotometer (Montreal Biotech, Kirkland, QC, Canada). All extracted DNA samples were pooled according to treatment conditions (SHAM, SG, DS, BPD/DS), time of sampling (week 0, week 2, 8, sacrifice), and location (alimentary limb, biliopancreatic limb, common limb, and feces) which resulted in a total of 125 DNA samples.
Data are presented as means ± standard errors of the mean (SEM). Statistical comparisons between groups were performed using one-way analysis of variance (ANOVA) followed by Bonferroni with three planned comparisons (SHAM vs SG, DS, BPD/DS). When needed, data were square root transformed to satisfy the variance normality criterion. Body weight and gross energy intake curves were analyzed using two-way ANOVA to determine the main interaction effect of surgery and time (GraphPad Prism version 7.00). Results were considered significant at P < 0.05.
Body Weight and Tissues Weights
Effects of BPD/DS, DS, SG, and SHAM surgery on adipose tissues, liver, and spleen on the eighth week post-surgery. Data are shown as means ± SEM. ****P < 0.0001 vs SHAM
7.3 ± 0.6
7.3 ± 0.6
2.2 ± 0.1****
2.0 ± 0.2****
7.3 ± 0.7
6.9 ± 1.1
0.6 ± 0.0****
1.2 ± 0.2****
Sum of WATs
14.6 ± 1.2
14.2 ± 1.6
2.8 ± 0.1****
3.3 ± 0.4****
0.8 ± 0.0
0.7 ± 0.0
0.2 ± 0.0****
0.2 ± 0.0****
22.6 ± 0.4
22.3 ± 1.1
15.3 ± 1.2****
14.9 ± 0.2****
1.3 ± 0.0
1.3 ± 0.0
0.8 ± 0.0****
0.8 ± 0.0****
During the first week after surgeries, there was no difference in GEI between groups. On days 8 and 14, BPD/DS exhibited a lower GEI than SHAM (P = 0.0027 and P < 0.0001; Fig. 1c). On day 24, DS and BPD/DS showed a significant reduction in GEI compared with SHAM (P = 0.0083 and P = 0.0154, respectively; Fig. 1c). Six weeks after surgery, only BPD/DS showed a significant reduction in GEI compared with SHAM (P = 0.0166; Fig. 1c). The GEI of SG rats was not different from that of SHAM rats (P > 0.9999) except on day 8 (P = 0.0001). There was no difference in the DEI of SG versus that of SHAM rats (P > 0.9999). DEI was lower in DS and BPD/DS than that in SHAM (P = 0.0002 and P = 0.0007, respectively; Fig. 1d). This was mostly attributable to the increased fecal energy loss caused by malabsorption in both DS and BPD/DS rats .
Gastrointestinal Hormones and Glucose Metabolism
Composition of Gut Microbiota over Time After DS and BPD/DS Surgeries
Composition of Gut Microbiota by DS and BPD/DS Along the Small Intestine
At the genus level, DS and BPD/DS promoted significant levels of Bifidobacterium and lower levels of the Peptostreptococcaceae and Clostridiaceae in the common and alimentary limbs as seen in fecal samples (Fig. 4d).
One primary goal of the present study was to examine the effects of the BPD/DS on the gut microbiota in rats, in which BPD/DS largely replicates the beneficial metabolic effects seen in humans [3, 4, 17]. We found that the fecal microbiota of BPD/DS rats significantly differs from that of SHAM animals. A decline in the diversity and richness of gut microbiota was seen in BPD/DS rats, as revealed by the Shannon and the Chao1 indices. The effects seemed less apparent at week 8, but nonetheless remained significant except for Chao1 in BPD-DS, possibly because of the apparent variability of the scores in the latter group. Furthermore, analysis of the microbial profile demonstrated a major shift from a microbiota dominated by Clostridiales prior to the surgery (or in SHAM rats) to a microbiota highly concentrated in Bifidobacteriales soon post-surgery. Since BPD/DS includes two surgical components, namely the SG and the DS, which distinctly influence energy homeostasis and metabolism [4, 6], we also aimed at dissecting the respective contribution of those components on the effect on gut microbiota. We found that DS, similar to BPD/DS, caused marked alterations in the fecal microbiota compared with SHAM or SG surgery. Finally, as the BPD/DS divides the gut into three functional segments, namely the alimentary, biliopancreatic, and common limbs, we were interested in looking at the microbiota in each of those segments. We observed that the gut microbiota within the alimentary and common limbs mirrored that of the feces as it exhibited a high content in Bifidobacteriales. On the other hand, the microbiota of the biliopancreatic limb differs from that of the two other limbs as it contains a substantial amount of Actinomycetales.
The present results confirmed the ability of certain bariatric surgical procedures to markedly affect the gut microbiota in humans [18, 19] as well as in laboratory rodents . Similar to BPD/DS in this study, RYGB in a previous report appeared to lower the diversity of gut microbiota while reducing the proportion of Clostridiales compared with SHAM surgery . However, unlike RYGB, BPD/DS considerably elevated the proportion of Bifidobacteriales as represented by increased abundance of the Bifidobacterium genus. That bariatric procedures may lower the diversity of the gut microbiota while reducing the proportion of Clostridiales has also been reported in humans before [13, 19, 22].
The mechanisms whereby BPD/DS affects the gut microbiota remain to be fully described. We report here the importance of the malabsorptive component of the BPD/DS in altering the composition of the microbiota. Indeed, the gut microbiota of the DS and BPD/DS rats were comparable and different from that of SG and SHAM rats. SG rats presented a similar microbial composition compared with SHAM rats, in agreement with previous observation . Malabsorption is inherent to the DS component of the BPD/DS surgery and likely explains the presence of a gut microbiota that appears specific to the BPD/DS and different from RYGB , which is not described as a priori being a malabsorptive surgery . Our rat BPD/DS procedure has been reported to enhance fecal energy loss and thus cause malabsorption [5, 6]. That the presence of undigested digestible nutrients in the lower gut can alter the microbiota appears plausible. However, how such a phenomenon could elevate the proportion of the bacteria from the Bifidobacteriales order warrants further investigation. It seems unlikely that the change in the microbiota is attributable to the biliopancreatic secretion per se. In fact, the changes seen in the fecal microbiota were not only seen in the common limb, where the biliopancreatic secretion is derived, but also in the alimentary limb, which is derived from the biliopancreatic secretion. Furthermore, the biliopancreatic limb exhibits a microbiota that differs from that of the alimentary and common limbs.
It was previously reported that bariatric procedures can lead to a pathological bacterial overgrowth in the small intestine referred to as the small intestine bacterial overgrowth (SIBO) syndrome . Such a syndrome was seen most of the times following jejunoileal bypass (JIB) , a bariatric procedure that is no longer used, in part because of its inducing effects on bacterial overgrowth. In fact, JIB created a long partially-disconnected segment of the small bowel  that emerged as being very propitious for bacterial overgrowth . SIBO has also been reported following RYGB but in a minority of cases  and it would seem unlikely that the shifts of bacterial orders seen in this study be due to a pathological bacterial overgrowth. In fact, one can argue that the increase in the Bifidobacteriales in BPD-DS and DS rats in this study was attributable to rather a change in the proportion of bacteria than to bacterial overgrowth.
The changes in the microbiota seen in BPD/DS and DS rats were associated with beneficial effects of the two malabsorptive procedures. Indeed, both BPD/DS and DS in this study reduced fat deposition and improved insulin sensitivity, as previously reported  and as suggested from the HOMA-IR values in Supplementary Fig. 1. The SG surgery, as performed in this study, did not induce any change in weight gain, metabolic variables, and gut microbiota. As previously discussed [5, 6], the occurrence of metabolic long-lasting metabolic effects following SG likely appears to depend on the proportion of the stomach removed. In this study as well as in previous ones [5, 6], we removed 60% of the stomach as compared with 80% in studies showing reducing effects of SG on body fat [28, 29]. Given that changes in the microbiota were only seen in groups with body composition changes, one may thus argue that the microbiota shift following BPD/DS is a consequence of the concomitant lower fat gain. Such a possibility appears unlikely as the alteration in the microbiota composition appears specific to BPD/DS; RYGB has been reported to cause weight loss and changes in gut microbiota distinct from that observed in BPD/DS rats . Although a causal relationship between the microbiota shift and beneficial effects of the BPD/DS and DS cannot readily be established, one can reason that the microbiota composition associated with the malabsorptive procedures might confer health benefits. In fact, the increased proportion of bacteria from the Bifidobacteriales order was linked to the increased abundance of reads assigned to the genus Bifidobacterium which may confer health benefits [30, 31, 32, 33] to the host. The predominance of Bifidobacterium in the gut microbiota could reduce low-grade inflammation  as well as underlying the raised levels of GLP-1 and PYY following BPD/DS . The latter hormones cause satiating effect [36, 37, 38], and GLP-1, which is strongly stimulated in BPD/DS animals [5, 6], is seen as one of the most potent incretins [8, 9, 39]. One however needs to remain cautious in linking the rise in Bifidobacterium to the beneficial effects of the surgery as one cannot accurately estimate from the present data how much of the increased relative abundance of Bifidobacteriales was due to the drop of Clostridiales versus the true growth in Bifidobacteriales.
Altogether the results of the present study suggest that nutrient malabsorption, while reducing fat deposition and improving glucose metabolism, also alters gut microbiota composition, leading to the beneficial effects of DS and BPD/DS. We speculate that the positive outcomes of both surgeries may be enhanced through the modulation of gut microbiota and, more specifically, by the increased proportional abundance of Bifidobacterium throughout the gastrointestinal tract.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
All applicable institutional and/or national guidelines for the care and use of animals were followed. The protocol was approved by the Université Laval Animal Care and Use Committee, and animals were cared according to the Canadian Guide for the Care and Use of Laboratory Animals.
- 1.World Health Organization. Obesity: Preventing and Managing the Global Epidemic: Report on a WHO consultation. (WHO technical report series 894).Geneva, Switzerland: World Health Organization; 2000.Google Scholar
- 9.Laferrère B. (2016). Bariatric surgery and obesity: influence on the incretins. Int J Obes Suppl, 6(Suppl 1), S32-S36.Google Scholar
- 22.Graessler J, Qin Y, Zhong H, et al. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharm J. 2013;13(6):514–22.Google Scholar
- 33.Mangin I, Dossou-Yovo F, Leveque C, et al. Oral administration of viable Bifidobacterium pseudolongum strain Patronus modified colonic microbiota and increased mucus layer thickness in rat. FEMS Microbiol Ecol. 2018;94(11)Google Scholar
- 34.Sanchis-Chordà J, Del Pulgar EMG, Carrasco-Luna J, et al. Bifidobacterium pseudocatenulatum CECT 7765 supplementation improves inflammatory status in insulin-resistant obese children. Eur J Nutr. 2018; https://doi.org/10.1007/s00394-018-1828-5
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.